Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | CFTR | P13569 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | GLA | P06280 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30775571 | 1.00 | NPSR1 (0.47) | NPSR1KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL9284710 | 0.83 | GRM5 (0.40) | NPSR1KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL4257399 | 0.82 | NPSR1 (0.47) | NPSR1KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL31663021 | 0.82 | NPSR1 (0.47) | NPSR1KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL29829085 | 0.81 | NPSR1 (0.50) | NPSR1KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL388845 | 0.81 | NPSR1 (0.50) | NPSR1KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL5747714 | 0.81 | NPSR1 (0.50) | NPSR1KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL31122089 | 0.81 | ALDH1A1 (0.46) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL2032423 | 0.81 | ALDH1A1 (0.46) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL262928 | 0.80 | GRM5 (0.54) | NPSR1KDM4EALDH1A1HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622909-B2 | Allosteric EGFR inhibitors and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12600722-B2 | Tetracyclic compounds as DGK inhibitors | INCYTE CORPORATION (US) | 2026-04-14 | — | — | US | disclosed |
| US-12600723-B2 | Tetracyclic compounds as DGK inhibitors | INCYTE CORPORATION (US) | 2026-04-14 | — | — | US | disclosed |
| US-12509451-B2 | Heteroaryl amide inhibitors of CD38 | NAPA THERAPEUTICS LIMITED (IM) | 2025-12-30 | — | — | US | disclosed |
| US-20250340535-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250340534-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12391671-B2 | Allosteric EGFR inhibitors and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| CN-120004861-A | Allosteric EGFR inhibitors and methods of use thereof | 达纳-法伯癌症研究所股份有限公司 | 2025-05-16 | — | — | CN | disclosed |
| US-20250066358-A1 | Inhibitors of Menin-MLL Interaction | BALA THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| US-7414060-B2 | Pyridine-2-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-08-19 | — | — | US | disclosed |
| EP-1732933-B1 | COMPOUNDS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1732933-B1 | COMPOUNDS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20070208003-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY | 2007-09-06 | — | — | US | disclosed |
| US-20070208003-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY | 2007-09-06 | — | — | US | disclosed |
| US-20070208003-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY | 2007-09-06 | — | — | US | disclosed |
| EP-1732933-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060199960-A1 | e.g. 6-Methyl-3-(pyridin-3-ylamino)-pyridine-2-carboxylic acid (4-methyl-thiazol-2-yl)-amide; metabotropic glutamate receptor antagonists (mGluR); central nervous system disorders, antidepressant, anxiolytc agent; psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders | HOFFMANN-LA ROCHE INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2005097805-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622909-B2 | Allosteric EGFR inhibitors and methods of use thereof | EGFR, ERBB3, ERBB2 | NPSR1 1201/4885KDM4E 1366/4885ALDH1A1 4245/4885 |
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, BMI1 | NPSR1 4750/4885KDM4E 136/4885ALDH1A1 3650/4885 |
| US-20250340535-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | NPSR1 3651/4885KDM4E 3185/4885ALDH1A1 4739/4885 |
| US-12391671-B2 | Allosteric EGFR inhibitors and methods of use thereof | EGFR, ERBB2, ERBB3 | NPSR1 3651/4885KDM4E 3185/4885ALDH1A1 4739/4885 |
| US-20250340534-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | NPSR1 3651/4885KDM4E 3185/4885ALDH1A1 4739/4885 |
| US-20250066358-A1 | Inhibitors of Menin-MLL Interaction | MLLT1, MEN1, BMI1 | NPSR1 4750/4885KDM4E 136/4885ALDH1A1 3650/4885 |
| US-12509451-B2 | Heteroaryl amide inhibitors of CD38 | CD38, FCGRT, BCL6 | NPSR1 902/4885KDM4E 2756/4885ALDH1A1 215/4885 |
| US-20060199960-A1 | e.g. 6-Methyl-3-(pyridin-3-ylamino)-pyridine-2-carboxylic acid (4-methyl-thiazol-2-yl)-amide; metabotropic glutamate receptor antagonists (mGluR); central nervous system disorders, antidepressant, anxiolytc agent; psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders | GRM3, GRM2, GRM1 | NPSR1 223/4885KDM4E 965/4885ALDH1A1 2246/4885 |
| US-12600723-B2 | Tetracyclic compounds as DGK inhibitors | DGKB, DGKA, NR2C2 | NPSR1 412/4885KDM4E 4662/4885ALDH1A1 3817/4885 |
| US-20070208003-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | PCSK9, LIPC, APOB | NPSR1 566/4885KDM4E 1101/4885ALDH1A1 1384/4885 |
| US-12600722-B2 | Tetracyclic compounds as DGK inhibitors | DGKB, DGKA, DGKK | NPSR1 662/4885KDM4E 4606/4885ALDH1A1 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.